Company Filing History:
Years Active: 2019-2023
Title: Thierry Champion: Innovator in Cancer Treatment
Introduction
Thierry Champion is a notable inventor based in Saint Julien en Genevois, France. He has made significant contributions to the field of cancer treatment through his innovative research and development of antibody-drug conjugates. With a total of 5 patents to his name, Champion's work is paving the way for new therapeutic options in oncology.
Latest Patents
Champion's latest patents include groundbreaking inventions such as the IGF-1R antibody-drug-conjugate and its use for the treatment of cancer. This invention relates to an antibody-drug-conjugate capable of binding to IGF-1R, which comprises an antibody conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also encompasses methods of treatment and the application of this antibody-drug-conjugate for cancer therapy. Another significant patent is the IGF-1R antibody and its use as an addressing vehicle for cancer treatment. This invention involves a monoclonal antibody capable of binding to IGF-1R, along with the amino and nucleic acid sequences coding for the antibody. It highlights the potential of this antibody to induce internalization of IGF-1R, allowing it to be used in conjunction with other anti-cancer compounds.
Career Highlights
Throughout his career, Thierry Champion has worked with prominent companies in the pharmaceutical industry, including Pierre Fabre Medicament and Pierre Fabre Médicament. His experience in these organizations has contributed to his expertise in developing innovative cancer treatments.
Collaborations
Champion has collaborated with notable colleagues such as Liliane Goetsch and Matthieu Broussas. These partnerships have further enhanced his research and development efforts in the field of oncology.
Conclusion
Thierry Champion's contributions to cancer treatment through his innovative patents and collaborations highlight his role as a leading inventor in the pharmaceutical industry. His work continues to inspire advancements in therapeutic options for patients battling cancer.